A randomized phased two open label study of Nivolumab plus standard dose Bevacizumab versus Nivolumab and low dose Bevacizumab in recurrent glioblastoma

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/17 → 1/1/21

Funding

  • Cleveland Clinic: $2,206,820.00